12th Asian Biologics and Biosimilars Congress
Conference
Medical
Mon, Aug 20, 2018, 09:00 AM - Tue, Aug 21, 2018, 04:00 PM
http://biosimilars-biologics.pharmaceuticalconferences.com/a
Contact details
Victorya Jones
biosimilarsasia@pharmaceuticalconferences.org
7025085200
05-04-2018
Organiser : Conference series llc LTD
Location details
Tokyo, Japan
Radisson Narita, Tokyo 650-35 Nanae, Tomisato-Shi Narita 286-0221, Japan, http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific/
Tokyo
Tokyo - Japan
650-35
Asian
Biosimilars 2018 is a specially designed cluster conference. The main theme
of the conference is " Biologics & Biosimilars: Power of the Past -
Force of the Future" which covers a wide range of critically important
sessions. All over the world, there are more than 380 companies producing Biologics
and Biosimilars and 55,000 industrialists doing their research work.
The global
Biosimilars market (Follow-On-Biologics) is expected to reach $26.5Billion
by 2020 growing at a CAGR of 49.1% from 2015 to 2020 whereas the global
biosimilars market alone is expected to
reach $6.22 Billion by 2020 from $2.29 Billion in 2015, at a
compound annual growth rate (CAGR) of 22.1% from 2015 to 2020. There are
currently more biosimilar
products in development across the Asia-Pacific region than anywhere else
in the world, leading to a wealth of opportunities for investigators and
patients to take part in biosimilar
clinical trials. Countries in Asia, particularly India, Singapore, Korea,
Japan and China, are the attractive locations to build bio development and bio
manufacturing capabilities.Conference Tracks
1.
Latest Biosimilars in Asian Scenario
2.
Regulatory Approach for Biosimilars
3.
Challenges in Developing Biosimilars
4.
Biosimilar Market and Cost Analysis
5.
Pharmacovigilance of Biosimilars
6.
Biosimilars Research Pipeline
7.
Globalization of Biosimilars
8.
Emerging Trends in Biosimilars
9.
Clinical Studies on Biosimilars
10. Emerging Biosimilars in Therapeutics
11. Biosimilars Analytical Strategies
12. Legal Issues and BPCI Act
13. Intellectual Property Rights
14. Brexit Effect on Biosimilars
15. BCS & IVIVC Based Biowaivers
16. Biosimilar Companies and Market Analysis
17. Bioequivalence Assessment
18. Entrepreneurs Investment Meet
